Mural Oncology plc was a clinical-stage immuno-oncology company whose updates centered on cytokine-based immunotherapies for cancer, its protein engineering platform, and the discontinuation of clinical development for nemvaleukin alfa. Company news also covered operating and financial results, capital-structure disclosures, Irish Takeover Rules announcements, shareholder voting materials, and governance matters.
The company completed an acquisition through an Irish scheme of arrangement in December 2025, and admission of its ordinary shares to trading on the Nasdaq Global Market was cancelled. MURA is a historical public-company issuer shaped by its biotechnology program history and completed corporate-status change.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.